CN110156815A - 12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法 - Google Patents

12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法 Download PDF

Info

Publication number
CN110156815A
CN110156815A CN201910479638.0A CN201910479638A CN110156815A CN 110156815 A CN110156815 A CN 110156815A CN 201910479638 A CN201910479638 A CN 201910479638A CN 110156815 A CN110156815 A CN 110156815A
Authority
CN
China
Prior art keywords
benzoyl
hydrogen
benzo
pyridine
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910479638.0A
Other languages
English (en)
Inventor
程斌
李运通
张昕平
李慧
胡汉巍
翟宏斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lanzhou University
Original Assignee
Lanzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanzhou University filed Critical Lanzhou University
Priority to CN201910479638.0A priority Critical patent/CN110156815A/zh
Publication of CN110156815A publication Critical patent/CN110156815A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

本发明涉及有机合成化学领域，具体是涉及一种12a氢‑苯并[f]吡啶[1,2‑d][1,4]硫氮卓及其制备方法，分子中含有硫氮卓杂环骨架和二氢吡啶结构单元，并具有丰富的多种官能团取代。结构式为：

Description

12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法
技术领域
本发明涉及有机合成化学领域，具体是涉及一种12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法。
背景技术
含硫化合物以不同的存在形式服务于人类生活的各个方面。含硫有机化合物在药物分子中大量存在，例如噻吩、苯并噻吩等常见含硫杂环。本发明所涉及的12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓类化合物为本发明首次合成，分子中含有硫氮卓杂环骨架和二氢吡啶结构单元，并具有丰富的多种官能团取代。因其结构新颖，包含常见的药效团，多个杂环稠和，可能使该类化合物具有潜在的生物活性，在生物医药等领域可能成为药物先导化合物。
发明内容
本发明的主要目的在于提供了一种12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法。该方法实现了由苯炔前体化合物与含硫内鎓盐，在氟化钾/18-冠-6作为催化剂的条件下，一步简洁高效合成12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓类化合物。
本发明所述的化合物是如Ⅰ所示的化合物—12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓(12aH-benzo[f]pyrido[1,2-d][1,4]thiazepine)；
其中：
R1为氢、2,3-二甲基、苯环、2,3-二氧杂环、2,3-环戊烷、2,3-二氟；
R2为11-甲基或9,10苯环稠和取代；
R3为甲酯、乙酯、叔丁酯、三氟甲基、苯甲酰基；
R4为甲酯、乙酯、苯甲酰基、4-甲氧基苯甲酰基、4-甲基苯甲酰基、4-溴苯甲酰基、4-硝基苯甲酰基、呋喃甲酰基。
本发明的12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓(12aH-benzo[f]pyrido[1,2-d][1,4]thiazepine)的合成方法如下所示:
即将通式Ⅱ所示化合物、通式Ⅲ所示化合物、氟化钾/18-冠-6在室温条件下溶解于乙腈溶剂中，反应物Ⅱ反应完全后，将反应混合物在减压条件下除去有机溶剂，柱层析洗脱得到目标化合物Ⅰ。其中：
R1为氢、2,3-二甲基、苯环、2,3-二氧杂环、2,3-环戊烷、2,3-二氟；
R2为11-甲基或9,10苯环稠和取代；
R3为甲酯、乙酯、叔丁酯、三氟甲基、苯甲酰基；
R4为甲酯、乙酯、苯甲酰基、4-甲氧基苯甲酰基、4-甲基苯甲酰基、4-溴苯甲酰基、4-硝基苯甲酰基、呋喃甲酰基。
本发明优选的12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓的合成方法是，使用氟化钾作/18-冠-6作为催化剂，以乙腈作为溶剂。
进一步，反应时化合物Ⅱ、化合物Ⅲ、氟化钾/18-冠-6的最优摩尔比(即当量比)为Ⅱ：Ⅲ：氟化钾/18-冠-6＝1.0:1.5:2.0，最优浓度为0.1M，即0.1摩尔每升。
更进一步，在硅胶柱层析时，所用的洗脱液为石油醚与乙酸乙酯的混合溶剂，且体积比V石油醚:V乙酸乙酯＝10:1～5:1。
本发明涉及的方法，具有的技术效果：
一方面使用含硫内鎓盐作为12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓化合物中硫原子的引入试剂，另一方面该类内鎓盐中吡啶也可以作为活性单元参与反应，这不仅极大的提高了该类内鎓盐的原子经济性，同时也使产物中引入二氢吡啶结构单元。12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓类化合物的骨架结构本发明属于首次合成。该类化合物结构新颖，具有潜在的生物活性，从而让其具有进一步研究和应用的价值。
具体实施方式
本发明以下结合具体实施例进行解说。
以下是本发明制备化合物的最佳实施例。在以下所有实施例中，核磁谱检测通过Varian 300,Bruker400,JEOL400and Varian 600MHz仪器在CDCl3、(CD3)2CO或d6-DMSO中获得。δ值为内标相对值(CDCl3定标δ7.26 1H NMR和77.0013C NMR；(CD3)2CO定标δ2.05 1H NMR和29.84 13C NMR；d6-DMSOδ2.501H NMR和39.5213C NMR)。高分辨质谱(HRMS)通过4Gquadrupole time-of-flight(QTof)质谱仪器得到。
实施例1
实施例1的反应式，具体使用的化合物Ⅱ-1和化合物Ⅲ-1以及产物Ⅰ-1结构如下所示。实验表明本发明优选的氟源/18-冠-6作为催化剂，优选的有机溶剂为乙腈，最优的原料摩尔比为化合物Ⅱ：化合物Ⅲ：氟化钾/18-冠-6＝1.0:1.5:2.0，最优浓度为0.1M。
具体实验步骤是：将90mg(0.30mmol，1.0当量)的化合物Ⅱ-1和114mg(0.450mmol，1.5当量)的化合物Ⅲ-1溶于3mL的乙腈中，加入35mg(0.60mmol，2.0当量)的氟化钾和159mg(0.60mmol，2.0当量)的18-冠-6，于室温下反应。薄层色谱监测反应物Ⅱ-1反应完全，将反应混合物在水泵减压下旋转蒸发除去溶剂乙腈。残留物以200-300目硅胶，洗脱液(体积比V石油醚:V乙酸乙酯＝10:1～5:1)柱层析得到Ⅰ-1所示化合物58mg，其产物经过核磁(氢谱、碳谱)、高分辨质谱鉴定。
产物Ⅰ-1为黄色固体，产率为59％；熔点：59-60℃.1H NMR(400MHz,CDCl3)δ7.46–7.41(m,1H),7.35–7.31(m,1H),7.31–7.26(m,2H),6.73(d,J＝6.0Hz,1H),6.27(dd,J＝9.6,5.6Hz,1H),5.77(d,J＝7.6Hz,1H),5.48(dd,J＝9.6,6.4Hz,1H),5.26–5.20(m,1H),3.81(s,3H),3.78(s,3H)；13C NMR(100MHz,CDCl3)δ165.4,165.0,145.3,141.6,135.1,132.0,128.6,128.2,127.6,126.6,124.3,116.6,105.6,103.5,55.8,53.0,52.7；ESI-HRMSm/z calcd for C17H15NO4S+H+330.0795,found 330.0797.
实施例2-18
制备本发明的其它化合物(化合物Ⅰ-2至化合物Ⅰ-18)的实施例所用的方法与实施例1相同，反应条件如下：化合物Ⅱ(0.3mmol)、化合物Ⅲ(1.5当量)溶于3mL的乙腈中，加入氟化钾量为35mg(0.60mmol，2.0当量)、18-冠-6量为159mg(0.60mmol，2.0当量)，室温下反应。
所得产物表征如下：
产物Ⅰ-2为黄色固体，产率为48％；熔点：68-69℃.1H NMR(400MHz,CDCl3)δ7.48–7.42(m,1H),7.36–7.32(m,1H),7.30–7.26(m,2H),6.69(d,J＝6.0Hz,1H),6.27(dd,J＝9.6,5.6Hz,1H),5.80(d,J＝7.2Hz,1H),5.49(dd,J＝9.6,6.0Hz,1H),5.24–5.19(m,1H),4.33–4.20(m,4H),1.33(t,J＝7.2Hz,3H),1.30(t,J＝7.2Hz,3H)；13C NMR(100MHz,CDCl3)δ165.0,164.6,145.2,141.8,135.5,132.1,128.6,128.1,127.7,127.0,124.5,116.5,105.3,104.6,62.3,61.8,56.0,14.1,13.8；ESI-HRMS m/z calcd for C19H19NO4S+H+358.1108,found 358.1111.
产物Ⅰ-3为黄色固体，产率为54％；熔点：74-75℃.1H NMR(400MHz,CDCl3)δ8.00–7.94(m,2H),7.94–7.85(m,2H),7.56–7.31(m,10H),7.10(d,J＝6.0Hz,1H),6.23(dd,J＝9.2,5.6Hz,1H),5.61(d,J＝7.2Hz,1H),5.58–5.52(m,1H),5.01–4.94(m,1H)；13C NMR(100MHz,CDCl3)δ192.3,191.8,148.2,142.8,137.4,136.1,135.9,133.4,132.6,131.6,129.9,129.0,128.7,128.6(2C),128.4,128.2,128.0,125.4,119.2,115.6,104.6,55.8；ESI-HRMS m/z calcd for C27H19NO2S+H+422.1209,found 422.1212.
产物Ⅰ-4为黄色固体，产率为58％；熔点:>200℃.1H NMR(400MHz,CDCl3)δ8.00–7.92(m,2H),7.59–7.54(m,1H),7.50–7.42(m,3H),7.41–7.37(m,1H),7.36–7.27(m,2H),6.58(d,J＝6.0Hz,1H),6.37(dd,J＝9.6,5.6Hz,1H),5.80(d,J＝7.2Hz,1H),5.55–5.48(m,1H),5.24–5.18(m,1H),3.43(s,3H)；13C NMR(75MHz,CDCl3)δ191.2,164.3,142.3,138.1,136.7,134.9,133.0,131.3,130.0,129.5,128.6,128.4,128.3,128.2,125.4,124.1,114.6,103.5,56.3,52.5；ESI-HRMS m/z calcd for C22H17NO3S+H+376.1002,found376.1004.
产物Ⅰ-5为黄色固体，产率为57％；熔点：122-123℃.1H NMR(400MHz,CDCl3)δ8.01–7.95(m,2H),7.43(dd,J＝7.2,2.0Hz,1H),7.38(dd,J＝7.2,1.6Hz,1H),7.33–7.26(m,2H),6.98–6.93(m,2H),6.48(d,J＝6.0Hz,1H),6.36(dd,J＝9.2,5.2Hz,1H),5.81(d,J＝6.8Hz,1H),5.52–5.46(m,1H),5.22–5.16(m,1H),3.88(s,3H),3.44(s,3H)；13C NMR(100MHz,CDCl3)δ189.8,164.3,163.6,142.4,136.9,134.8,132.0,131.2,130.4,129.4,128.5,128.3,128.1,125.6,125.5,114.1,113.7,103.0,56.4,55.4,52.4；ESI-HRMS m/z calcdfor C23H19NO4S+H+406.1008,found 406.1008.
产物Ⅰ-6为黄色固体，产率为57％；熔点：131-132℃.1H NMR(400MHz,CDCl3)δ7.88(d,J＝7.6Hz,2H),7.43(d,J＝7.2Hz,1H),7.38(d,J＝7.2Hz,1H),7.33–7.24(m,4H),6.52(d,J＝6.0Hz,1H),6.36(dd,J＝9.2,5.6Hz,1H),5.80(d,J＝7.6Hz,1H),5.54–5.46(m,1H),5.23–5.16(m,1H),3.43(s,3H),2.42(s,3H)；13C NMR(100MHz,CDCl3)δ190.8,164.3,143.9,142.4,137.4,134.8,134.0,131.2,130.2,129.7,129.1,128.5,128.3,128.1,125.4,125.0,114.3,103.2,56.4,52.4,21.7；ESI-HRMS m/z calcd for C23H19NO3S+H+390.1158,found 390.1161.
产物Ⅰ-7为红色固体，产率为37％；熔点：148-149℃.1H NMR(400MHz,CDCl3)δ7.82(d,J＝8.4Hz,2H),7.61(d,J＝8.4Hz,2H),7.44(dd,J＝7.6,1.6Hz,1H),7.40–7.27(m,3H),6.63(d,J＝6.0Hz,1H),6.36(dd,J＝9.2,5.6Hz,1H),5.77(d,J＝7.6Hz,1H),5.56–5.47(m,1H),5.26–5.18(m,1H),3.50(s,3H)；13C NMR(100MHz,CDCl3)δ190.2,164.4,142.4,138.5,135.5,134.8,131.7,131.4,131.1,129.8,128.7,128.5,128.4,128.0,125.4,122.8,114.9,103.8,56.1,52.7；ESI-HRMS m/z calcd for C22H16BrNO3S+H+454.0107,found454.0112.
产物Ⅰ-8为红色固体，产率为35％；熔点：140-141℃.1H NMR(400MHz,CDCl3)δ8.30(d,J＝8.8Hz,2H),8.06(d,J＝8.8Hz,2H),7.46(d,J＝7.6Hz,1H),7.40–7.30(m,3H),6.82(d,J＝6.0Hz,1H),6.35(dd,J＝9.2,5.6Hz,1H),5.76(d,J＝7.2Hz,1H),5.57–5.51(m,1H),5.28–5.23(m,1H),3.56(s,3H)；13C NMR(100MHz,CDCl3)δ189.6,164.4,149.9,142.3,142.2,140.5,135.1,131.4,130.4,129.0(2C),128.9,128.4,125.2,123.6,119.6,115.9,104.8,55.9,52.9；ESI-HRMS m/z calcd for C22H16N2O5S+H+421.0853,found 421.0855.
产物Ⅰ-9为红色固体，产率为55％；熔点：120-121℃.1H NMR(400MHz,CDCl3)δ7.63(d,J＝0.8Hz,1H),7.45–7.39(m,2H),7.37(d,J＝3.2Hz,1H),7.33–7.27(m,2H),6.55(dd,J＝3.6,1.6Hz,1H),6.51(d,J＝6.0Hz,1H),6.35(dd,J＝9.6,5.6Hz,1H),5.77(d,J＝7.2Hz,1H),5.56–5.49(m,1H),5.26–5.18(m,1H),3.50(s,3H)；13C NMR(100MHz,CDCl3)δ178.2,164.4,151.9,147.2,141.8,138.9,134.6,131.4,129.8,128.7,128.2,125.4,122.3,119.6,114.9,112.2,103.9,56.3,52.7,(1C missing)；ESI-HRMS m/z calcd forC20H15NO4S+H+366.0795,found 366.0798.
产物Ⅰ-10为黄色固体，产率为51％；熔点：64-65℃.1H NMR(400MHz,CDCl3)δ8.05–8.00(m,2H),7.58–7.54(m,1H),7.51–7.46(m,2H),7.45–7.42(m,1H),7.39–7.24(m,3H),6.56(d,J＝6.4Hz,1H),6.36(dd,J＝9.6,5.6Hz,1H),5.82(d,J＝7.6Hz,1H),5.52–5.44(m,1H),5.23–5.16(m,1H),1.12(s,9H)；13C NMR(100MHz,CDCl3)δ191.0,162.5,142.7,138.9,136.6,135.2,133.1,131.2,130.4,130.0,128.5,128.4,128.3,128.2,125.4,122.8,114.3,102.8,83.8,56.3,27.1；ESI-HRMS m/z calcd for C25H23NO3S+H+418.1471,found418.1472.
产物Ⅰ-11为黄色固体，产率为40％；熔点：85-86℃.1H NMR(400MHz,CDCl3)δ7.38–7.31(m,2H),7.28–7.22(m,2H),6.36(dd,J＝9.2,5.6Hz,1H),5.99(d,J＝6.4Hz,1H),5.93(d,J＝6.4Hz,1H),5.52–5.46(m,1H),5.30–5.25(m,1H),4.31(q,J＝7.2Hz,2H),1.36(t,J＝7.2Hz,3H)；13C NMR(100MHz,CDCl3)δ164.1,142.0,132.1,130.7,129.9(q,J＝32.4Hz),129.1(d,J＝1.9Hz),128.5,128.3,127.8,125.5,121.4(d,J＝2.7Hz),120.5(q,J＝276.7Hz),113.4,104.5,62.9,57.0,13.8；ESI-HRMS m/z calcd for C17H14F3NO2S+H+354.0770,found 354.0774.
产物Ⅰ-12为黄色固体，产率为39％；熔点：79-80℃.1H NMR(400MHz,CDCl3)δ7.46–7.42(m,1H),7.28–7.26(m,3H),6.69(d,J＝6.0Hz,1H),5.74(d,J＝7.6Hz,1H),5.23–5.19(m,1H),5.15–5.09(m,1H),3.81(s,3H),3.79(s,3H),1.91(s,3H)；13C NMR(100MHz,CDCl3)δ165.6,165.3,145.4,142.4,135.4,132.8,132.1,128.7,128.2,127.7,126.2,112.2,109.2,103.1,56.2,53.1,52.7,20.4；ESI-HRMS m/z calcd for C18H17NO4S+H+344.0951,found 344.0956.
产物Ⅰ-13为黄色固体，产率为48％；熔点：75-76℃.1H NMR(400MHz,CDCl3)δ7.35(d,J＝7.6Hz,1H),7.19–7.14(m,1H),7.13–7.05(m,3H),6.99–6.93(m,1H),6.91–6.83(m,2H),6.56(d,J＝8.0Hz,1H),6.27(d,J＝6.0Hz,1H),6.12–6.05(m,1H),3.83(s,3H),3.60(s,3H)；13C NMR(100MHz,CDCl3)δ165.3,165.1,141.8,141.1,137.7,133.2,131.0,128.8,128.4,127.9,127.7,127.1,127.1,125.2,122.7,122.6,118.0,116.7,58.8,53.0,52.7；ESI-HRMS m/z calcd for C21H17NO4S+H+380.0951,found 380.0957.
产物Ⅰ-14为黄色固体，产率为42％；熔点：92-93℃.1H NMR(400MHz,CDCl3)δ7.23(s,1H),7.07(s,1H),6.72(d,J＝6.0Hz,1H),6.24(dd,J＝9.6,5.6Hz,1H),5.75(d,J＝7.2Hz,1H),5.50–5.43(m,1H),5.24–5.18(m,1H),3.80(s,3H),3.78(s,3H),2.25(s,3H),2.23(s,3H)；13C NMR(100MHz,CDCl3)δ165.6,165.3,145.2,139.2,137.4,136.9,133.2,131.5,128.9,126.8,124.2,116.9,105.5,103.9,55.8,53.0,52.7,19.7,19.3；ESI-HRMSm/z calcd for C19H19NO4S+H+358.1108,found 358.1110.
产物Ⅰ-15为黄色固体，产率为35％；熔点：130-131℃.1H NMR(400MHz,CDCl3)δ7.30(dd,J＝9.6,7.6Hz,1H),7.15(dd,J＝10.4,8.0Hz,1H),6.67(d,J＝6.0Hz,1H),6.29(dd,J＝9.5,5.6Hz,1H),5.78(d,J＝7.6Hz,1H),5.52–5.42(m,1H),5.28–5.22(m,1H),3.82(s,3H),3.78(s,3H)；13C NMR(100MHz,CDCl3)δ165.2,164.8,149.8(dd,J＝251.3,4.2Hz),148.5(dd,J＝251.4,4.9Hz),145.4,139.1(t,J＝4.1Hz),130.9(dd,J＝6.2,4.2Hz),126.8,125.0,121.5(d,J＝18.8Hz),117.4(d,J＝19.1Hz),116.2,105.8,103.3,55.1,53.2,52.9；ESI-HRMS m/z calcd for C17H13F2NO4S+H+366.0606,found 366.0609.
产物Ⅰ-16为黄色固体，产率为48％；熔点：91-92℃.1H NMR(400MHz,CDCl3)δ6.94(s,1H),6.88(s,1H),6.80(d,J＝6.0Hz,1H),6.24(dd,J＝9.6,5.6Hz,1H),6.00–5.93(m,2H),5.78–5.73(m,1H),5.48–5.41(m,1H),5.23–5.17(m,1H),3.80(s,3H),3.77(s,3H)；13CNMR(100MHz,CDCl3)δ165.4,165.1,148.0,147.1,145.3,136.8,126.8,126.5,124.5,117.0,112.8,108.6,105.5,103.4,101.5,55.4,53.1,52.7；ESI-HRMS m/z calcd forC18H15NO6S+H+374.0693,found 374.0695.
产物Ⅰ-17为黄色固体，产率为51％；熔点：68-69℃.1H NMR(400MHz,CDCl3)δ7.32(s,1H),7.20(s,1H),6.79(d,J＝6.0Hz,1H),6.24(dd,J＝9.6,5.6Hz,1H),5.75(d,J＝7.6Hz,1H),5.50–5.43(m,1H),5.24–5.19(m,1H),3.80(s,3H),3.78(s,3H),2.95–2.83(m,4H),2.12–2.02(m,2H)；13C NMR(100MHz,CDCl3)δ165.6,165.3,145.2,145.0,144.8,139.5,132.1,128.3,126.7,124.2,123.7,117.1,105.5,103.7,55.8,53.0,52.7,32.8,32.6,25.3；ESI-HRMS m/z calcd for C20H19NO4S+H+370.1108,found 370.1111.
产物Ⅰ-18为黄色固体，产率为43％；熔点：121-122℃.1H NMR(400MHz,CDCl3)δ7.99(s,1H),7.84–7.80(m,1H),7.78–7.75(m,1H),7.73(s,1H),7.54–7.47(m,2H),6.86(d,J＝5.6Hz,1H),6.36(dd,J＝9.2,5.6Hz,1H),5.75–5.70(m,1H),5.62–5.55(m,1H),5.31–5.25(m,1H),3.82(s,3H),3.82(s,3H)；13C NMR(100MHz,CDCl3)δ165.5,165.2,145.1,136.2,133.1,132.9,132.8,131.8,128.1,127.5,127.4,127.1,126.9,126.5,124.7,116.8,106.2,104.7,55.9,53.1,52.8；ESI-HRMS m/z calcd for C21H17NO4S+H+380.0951,found380.0957.
最后应说明的是：以上所述仅为本发明的优选实施例而已，并不用于限制本发明，尽管参照前述实施例对本发明进行了详细的说明，对于本领域的技术人员来说，其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换。凡在本发明的内容和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。

Claims (4)

1.12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓，其特征在于，结构式如Ⅰ所示，七元环含有氮硫两个杂原子的同时，还含有多个不同种类的取代基；
其中：R1为氢、2,3-二甲基、苯环、2,3-二氧杂环、2,3-环戊烷、2,3-二氟；
R2为11-甲基或9,10苯环稠和取代；
R3为甲酯、乙酯、叔丁酯、三氟甲基、苯甲酰基；
R4为甲酯、乙酯、苯甲酰基、4-甲氧基苯甲酰基、4-甲基苯甲酰基、4-溴苯甲酰基、4-硝基苯甲酰基、呋喃甲酰基。
2.根据权利要求1所述的12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓的制备方法，其特征在于，如下所示：
目标化合物Ⅰ的制备方法：将通式Ⅱ所示化合物、通式Ⅲ所示化合物、氟化钾和18-冠-6在室温条件下溶解于乙腈溶剂中，反应物Ⅱ反应完全后，将反应混合物在减压条件下除去有机溶剂，柱层析洗脱得到目标化合物Ⅰ；
反应物Ⅱ中：R1为氢、2,3-二甲基、苯环、2,3-二氧杂环、2,3-环戊烷、2,3-二氟；
反应物Ⅲ中：R2为11-甲基或9,10苯环稠和取代；R3为甲酯、乙酯、叔丁酯、三氟甲基、苯甲酰基；R4为甲酯、乙酯、苯甲酰基、4-甲氧基苯甲酰基、4-甲基苯甲酰基、4-溴苯甲酰基、4-硝基苯甲酰基、呋喃甲酰基。
3.根据权利要求2所述的12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓的制备方法，其特征在于，化合物Ⅱ、化合物Ⅲ、氟化钾和18-冠-6的摩尔比1.0:1.5:2.0:2.0，乙腈溶液浓度为0.1M。
4.根据权利要求2所述的12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓的制备方法，其特征在于，柱层析洗脱的硅胶柱层析，所用的洗脱液为石油醚与乙酸乙酯的混合溶剂，且体积比V石油醚:V乙酸乙酯＝10:1～5:1。
CN201910479638.0A 2019-06-04 2019-06-04 12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法 Pending CN110156815A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910479638.0A CN110156815A (zh) 2019-06-04 2019-06-04 12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910479638.0A CN110156815A (zh) 2019-06-04 2019-06-04 12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法

Publications (1)

Publication Number Publication Date
CN110156815A true CN110156815A (zh) 2019-08-23

Family

ID=67627084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910479638.0A Pending CN110156815A (zh) 2019-06-04 2019-06-04 12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法

Country Status (1)

Country Link
CN (1) CN110156815A (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110041290A (zh) * 2019-04-01 2019-07-23 兰州大学 2,5-二氢-1,4,5-硫二氮卓及其氧化物制备方法
CN111484476A (zh) * 2020-04-13 2020-08-04 深圳职业技术学院 3氢-1,2-二硫代2,2-二氧化物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102164605A (zh) * 2008-07-23 2011-08-24 美国卫生和人力服务部 用作抗疟药的疟原虫表面阴离子通道抑制剂
CN102807574A (zh) * 2011-05-30 2012-12-05 长春吉大天元化学技术股份有限公司 新型吡啶并硫氮七元环衍生物作为抗肿瘤药物、及其制备方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102164605A (zh) * 2008-07-23 2011-08-24 美国卫生和人力服务部 用作抗疟药的疟原虫表面阴离子通道抑制剂
CN102807574A (zh) * 2011-05-30 2012-12-05 长春吉大天元化学技术股份有限公司 新型吡啶并硫氮七元环衍生物作为抗肿瘤药物、及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JINHWAN SHIN ET AL.: "Synthesis of fused polycyclic 1,4-benzodiazepines via metal-free cascade[5+2]/[2+2] cycloadditions", 《ORG.LETT.》 *
SACHIN CHOUDHARY ET AL.: "One-pot synthesis of chiral tetracyclic dibenzo[b,f][1,4]oxazepine-fused 1,2-dihydropyridines (DHPs) under metal-free conditions", 《J.ORG.CHEM.》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110041290A (zh) * 2019-04-01 2019-07-23 兰州大学 2,5-二氢-1,4,5-硫二氮卓及其氧化物制备方法
CN111484476A (zh) * 2020-04-13 2020-08-04 深圳职业技术学院 3氢-1,2-二硫代2,2-二氧化物及其制备方法
CN111484476B (zh) * 2020-04-13 2021-06-22 深圳职业技术学院 3氢-1,2-二硫代2,2-二氧化物及其制备方法

Similar Documents

Publication Publication Date Title
CN106220581A (zh) 含氟杂环化合物及其制备方法
CN110156815A (zh) 12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法
CN110240568A (zh) 三取代哒嗪类衍生物及其制备方法
CN109790114A (zh) 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
CN110642803B (zh) 一种二氢噻唑杂环化合物的合成方法及在生物分子修饰中的应用
CN108373453A (zh) 三氮唑衍生物及其制备方法
CN104768955B (zh) 用于美登醇酰化的改进的方法
CN110105269A (zh) 基于非对称炔的1,4-二离子型含硫内鎓盐衍生物及其制备方法
CN113549051B (zh) 一种双酰胺类杀虫剂的合成方法
CA2645154C (en) Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
CN113234037A (zh) Z-2-(2-酰基亚甲基)噻唑烷-4-酮类衍生物及其制备方法和应用
CN110028451B (zh) 一种全取代吡唑衍生物制备方法
CN110054637A (zh) 一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合成方法
Heravi et al. One-pot multicomponent synthesis hexahydroquinoline derivatives in Triton X-100 aqueous micellar media
CN110105285A (zh) 三取代吡唑类衍生物及其制备方法
CN111116511A (zh) 一种苯并噻唑类生物硫醇探针及其制备方法和应用
Zheng et al. Access to thiazoline and spiro [indoline-3, 3′-thiophene] scaffolds via a formal [3+ 2] annulation reaction of crotonate-derived sulfur ylides and β-ketothioamides
CN105348194A (zh) 含氟菲啶衍生物及其制备方法
Grigorjeva et al. Novel synthesis of 2-trichloromethyl-4-vinyloxazoline and its derivatization by ring cleavage reactions
Benedini et al. Synthesis and NMR studies of thiazolidine‐4‐carboxylic acid derivatives containing a nitro ester function
Gangadasu et al. Synthesis, photochemical E (trans)→ Z (cis) isomerization and antimicrobial activity of 2-chloro-5-methylpyridine-3-olefin derivatives
Yadav et al. SN2 substitution reaction of 2-C-acetoxymethyl glycals catalyzed by iodine: a novel synthesis of 2-CN-arylamidomethyl glycals
CN110041290A (zh) 2,5-二氢-1,4,5-硫二氮卓及其氧化物制备方法
CN107513056A (zh) 一种含四氢呋喃基团的喹啉类化合物的合成方法
CN109384787A (zh) 一种一价银催化的氢化吡啶螺二氢吲哚环的合成方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190823